What is HC Wainwright's Estimate for DNLI FY2028 Earnings?

Key Points

• HC Wainwright has revised its FY2028 earnings estimate for Denali Therapeutics, predicting earnings per share of $0.81, down from a prior estimate of $0.85.
• The consensus estimate for Denali Therapeutics' current full-year earnings stands at ($2.71) per share, while HC Wainwright also projected FY2029 earnings at $2.11 EPS.
• Denali Therapeutics has a market capitalization of $2.07 billion, and its shares saw a trading price drop to $14.14 during midday trading on Thursday.

Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) - Equities researchers at HC Wainwright dropped their FY2028 earnings estimates for shares of Denali Therapeutics in a note issued to investors on Tuesday, August 12th. HC Wainwright analyst A. Fein now anticipates that the company will post earnings per share of $0.81 for the year, down from their previous estimate of $0.85. HC Wainwright has a "Buy" rating and a $32.00 price objective on the stock. The consensus estimate for Denali Therapeutics' current full-year earnings is ($2.71) per share. HC Wainwright also issued estimates for Denali Therapeutics' FY2029 earnings at $2.11 EPS.

Denali Therapeutics (NASDAQ:DNLI - Get Free Report) last announced its quarterly earnings data on Monday, August 11th. The company reported ($0.72) EPS for the quarter, beating the consensus estimate of ($0.74) by $0.02. During the same quarter last year, the firm posted ($0.59) earnings per share.

DNLI has been the subject of a number of other research reports. TD Cowen upgraded shares of Denali Therapeutics to a "strong-buy" rating in a research report on Monday, July 28th. Wedbush lowered their price target on shares of Denali Therapeutics from $32.00 to $30.00 and set an "outperform" rating for the company in a report on Wednesday, May 7th. Robert W. Baird lowered their target price on shares of Denali Therapeutics from $30.00 to $29.00 and set an "outperform" rating for the company in a report on Thursday, May 8th. Bank of America lowered their target price on shares of Denali Therapeutics from $28.00 to $27.00 and set a "buy" rating for the company in a report on Monday, May 19th. Finally, William Blair upgraded shares of Denali Therapeutics to a "strong-buy" rating in a report on Thursday, April 24th. One analyst has rated the stock with a hold rating, thirteen have given a buy rating and three have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Buy" and a consensus target price of $33.85.

Denali Therapeutics Price Performance

Shares of NASDAQ DNLI traded down $0.68 during midday trading on Thursday, hitting $14.14. The company had a trading volume of 402,489 shares, compared to its average volume of 1,406,641. The company has a quick ratio of 9.56, a current ratio of 10.27 and a debt-to-equity ratio of 0.01. Denali Therapeutics has a twelve month low of $10.57 and a twelve month high of $33.33. The business has a 50-day simple moving average of $14.29 and a two-hundred day simple moving average of $15.48. The firm has a market capitalization of $2.07 billion, a price-to-earnings ratio of -5.09 and a beta of 1.36.

Insiders Place Their Bets

In other news, CEO Ryan J. Watts sold 495,282 shares of the business's stock in a transaction on Wednesday, July 9th. The shares were sold at an average price of $15.00, for a total transaction of $7,429,230.00. Following the transaction, the chief executive officer directly owned 253,071 shares of the company's stock, valued at approximately $3,796,065. The trade was a 66.18% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 12.50% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in DNLI. Envestnet Asset Management Inc. raised its holdings in Denali Therapeutics by 34.5% in the fourth quarter. Envestnet Asset Management Inc. now owns 37,622 shares of the company's stock valued at $767,000 after acquiring an additional 9,643 shares in the last quarter. Raymond James Financial Inc. acquired a new stake in Denali Therapeutics in the fourth quarter valued at $533,000. Sterling Capital Management LLC raised its holdings in Denali Therapeutics by 589.9% in the fourth quarter. Sterling Capital Management LLC now owns 1,773 shares of the company's stock valued at $36,000 after acquiring an additional 1,516 shares in the last quarter. Barclays PLC raised its holdings in Denali Therapeutics by 8.7% in the fourth quarter. Barclays PLC now owns 278,067 shares of the company's stock valued at $5,666,000 after acquiring an additional 22,184 shares in the last quarter. Finally, XTX Topco Ltd acquired a new stake in Denali Therapeutics in the fourth quarter valued at $328,000. 92.92% of the stock is owned by institutional investors and hedge funds.

Denali Therapeutics Company Profile

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.